Early evidence points to promise, but uncertainties remain Researchers are finding signals that glucagon‑like peptide‑1 (GLP‑1) receptor agonists — drugs developed for diabetes and obesity — may reduce some forms of substance use and craving. Laboratory studi…
Early evidence points to promise, but uncertainties remain
Researchers are finding signals that glucagonlike peptide1 (GLP1) receptor agonists drugs developed for diabetes and obesity may reduce som… [+1651 chars]
